The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer
Open accessAbstract
In triple-negative breast cancer (TNBC), the benefit of combining chemotherapy with checkpoint inhibitors is still not very clear. We utilize single-cell RNA- and ATAC-sequencing to examine the immune cell dynamics in 22 patients with advanced TNBC treated with paclitaxel or its combination with the anti-PD-L1 atezolizumab. We demonstrate that high levels of baseline CXCL13 + T cells are linked to the proinflammatory features of macrophages and can predict effective responses to the combination therapy. In responsive patients, lymphoid tissue inducer (LTi) cells, follicular B (Bfoc) cells, CXCL13 + T cells, and conventional type 1 dendritic cells (cDC1) concertedly increase following the combination therapy, but instead decrease after paclitaxel monotherapy. Our data highlight the importance of CXCL13 + T cells in effective responses to anti-PD-L1 therapies and suggest that their reduction by paclitaxel regimen may compromise the clinical outcomes of accompanying atezolizumab for TNBC treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These cell subsets show different responses to anti-PD(L)-1 therapies,”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Applying ICB and combination therapies as neoadjuvant treatments provides an opportunity to observe immune cell dynamics in tumor microenvironment (TME) with temporal samples.”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,724
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,457
SCANPY: large-scale single-cell gene expression data analysis
Wolf, F. A., Angerer, P., & Theis, F. J. (2018) · Genome Biology · doi:10.1186/s13059-017-1382-0 · Cited by 8,881
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 792
New insights into cancer immune checkpoints landscape from single-cell RNA sequencing
Wang, Q., He, J., Lei, T., Li, X., Yue, S., Liu, C., & Hu, Q. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189298 · Cited by 4
He, L., Sui, X., Xiao, Y., Ji, P., & Gong, Y. (2025) · Journal of Pineal Research · doi:10.1111/jpi.70042 · Cited by 3
Dhruba, S. R., Sahni, S., Wang, B., Wu, D., Rajagopal, P. S., Gurevich, Y., Shulman, E. D., Sinha, S., Sammut, S., Caldas, C., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218101 · Cited by 4
Zhou, Y., Hu, Y., Zhang, L., Wu, T., Peng, S., Lin, C., Wang, Z., Zhou, Z., Zheng, J., Ren, J. M., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1064 · Cited by 3
Microenvironmental regulation of tumor initiation and development
ZHANG, Y., & Xiao-Fan, W. A. N. G. (2022) · Scientia Sinica Vitae · doi:10.1360/ssv-2022-0058 · Cited by 3
Self-citationKeeping track of the T cells that matter
Kaptein, P., & Thommen, D. S. (2022) · Nature Cancer · doi:10.1038/s43018-022-00432-8 · Cited by 3
Tarabay, J., Ren, D., Ifegu, I., Zada, S., Edwards, R. P., Chan, J. Y., Kuan, E. C., & Wang, B. (2023) · Journal of Clinical and Translational Pathology · doi:10.14218/jctp.2023.00018 · Cited by 3
Hou, P., Luo, Y., & Wu, N. (2023) · Open Life Sciences · doi:10.1515/biol-2022-0707 · Cited by 3
Perioperative immune checkpoint blockades improve prognosis of resectable non-small cell lung cancer
Tian, Y., Liu, Z., Pan, H., Zhu, H., Zou, N., Jiang, L., Li, Z., Huang, J., Hu, Y., & Luo, Q. (2024) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezae110 · Cited by 3
Self-citationLiu, Y., Dong, L., Ma, J., Chen, L., Fang, L., & Wang, Z. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01372-6 · Cited by 3
Modeling combination chemo‐immunotherapy for heterogeneous tumors
Chen, S., Hu, Z., & Zhou, D. (2025) · Quantitative Biology · doi:10.1002/qub2.98 · Cited by 3
Zhang, L., Yang, M., Zhang, Y., Lan, J., & Chen, Q. (2025) · Scientific Reports · doi:10.1038/s41598-025-02723-3 · Cited by 3
Self-citationInnate immunity as a target for novel therapeutics in triple negative breast cancer
Borgovan, T., Yanamandra, N., & Schmidt, H. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2096005 · Cited by 3
Wu, J., Lin, Z., Ji, D., Li, Z., Zhang, H., Lu, S., Wang, S., Liu, X., & Ao, L. (2022) · Cancers · doi:10.3390/cancers14163957 · Cited by 3
Redirecting cytotoxic lymphocytes to breast cancer tumors via metabolite-sensing receptorsPreprint
Kim, Y. M., Akana, R. V., Sun, C., Laveroni, O., & Jerby‐Arnon, L. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.21.644686 · Cited by 3
Rubio, Á. M., Oh, S., Roelandt, S., Stevens, D., Damme, E. V., Vermaelen, K. Y., Preter, K. D., & Everaert, C. (2024) · Scientific Reports · doi:10.1038/s41598-024-76982-x · Cited by 2
Oxeiptosis gene expression profiling identified TCN1 as a prognostic factor for breast cancer
Zhu, Y., Zhang, L., Zeng, D., Zhou, P., & Hu, J. (2024) · ONCOLOGIE · doi:10.1515/oncologie-2024-0397 · Cited by 2
Zhang, K., Nie, J., Wu, Y., Lu, Z., Qiu, Z., Li, Z., Zhong, Y., & Cheng, H. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.160811 · Cited by 2
Fan, P., Zhu, C., & Guan, X. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011899 · Cited by 2
Self-citationYuan, M., Liu, H., Huang, Y.-E., Hou, F., Wang, L., Wang, Q., & Jiang, W. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00992-9 · Cited by 2
Integrating multi-omics data to optimize immunotherapy in endometrial cancer: a comprehensive study
Guan, X., Cao, R., Liu, L., Ma, L., Gao, N., Yang, Y., Xiao, M., Du, R., Su, Y., Wang, Z., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02978-2 · Cited by 2
Self-citationFattori, S., Gorvel, L., Rouviére, M.-S., Granjeaud, S., Amara, A. B., Richaud, M., Boucherit, N., Tarpin, C., Pakradouni, J., Hedou, J. J., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-1285 · Cited by 2
Discovery of anti-tumor targets based on photo-affinity labeling
Kang, S.-S., Lan, J., Huang, H., Miao, Z.-Y., Jiang, J.-X., Xie, Y., Liu, S., Dai, W., Zeng, J.-L., Song, L.-R., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118248 · Cited by 2
Metronomic Chemotherapy in Breast Cancer: Unleashing the Potential of Combination Regimens
Liu, J. H., Mo, H., Li, Q., Cazzaniga, M. E., & Ma, F. (2025) · Cancer Innovation · doi:10.1002/cai2.70035 · Cited by 2
Self-citationElevated CD39 + T Cells Contribute to Immune Regulatory Imbalance in Systemic Lupus Erythematosus
Xiong, Z., Zong, Z., Zheng, X., Han, Q., Gao, Y., Bahabayi, A., Zhang, Z., & Liu, C. (2025) · Immunology · doi:10.1111/imm.70065 · Cited by 2
Self-citationZhang, W., Gai, Y., Qiao, M., Rowicki, M., Wei, Y., Hang, X., Wei, Z., Yang, H. S., Ye, X., Ju, H., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02472-9 · Cited by 3
Yuan, J., Fu, H., Han, W., & Huang, X. (2025) · BMC Neurology · doi:10.1186/s12883-025-04525-6 · Cited by 2
Sun, Q., Jin, X., Ma, Y.-T., Li, X., Peng, M., Yelebolati, S., & Cui, C. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149478 · Cited by 2
Li, Z., Wei, C., Wu, H., Wu, Z., Feng, X., Bian, F., Zeng, L., Zhang, P., Liao, Q., & Tang, R. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000004424 · Cited by 2
Breast cancer treatment using immunotherapy, advantages and disadvantages of immunotherapy
Rabbani, S. A., Kumar, R., El‐Tanani, M., Saini, M., Sharma, S., & El‐Tanani, Y. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33347-7.00005-1 · Cited by 2
Ji, T., Yang, B., Wang, M., Ji, H. G., Yang, H., & Liu, Y. T. (2026) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013912 · Cited by 2
Xing, Y., Zhong, R., Li, Q., Duan, X., Xu, M., Yu, M., Liu, C., He, J., Sun, Y., Wang, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69060-5 · Cited by 2
Self-citationYan, J., Qian, L., Chen, S., Karekad, M. M. A., Wu, X., Xu, M., & Xu, X. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1765550 · Cited by 3
Wang, Z., Dai, R., Wang, M., Zhang, Z., Lei, L., Li, Z., Han, K., Wang, Z., & Guo, Q. (2026) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-025-00811-6 · Cited by 2
Self-citationHe, S., Liu, X., & Lv, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1748257 · Cited by 2
Li, T., Huang, H., Zeng, Q., Zeng, L., Yang, Z., Shen, J., Li, S., Yang, H., Liu, Y., & Wu, C. (2026) · BMEMat · doi:10.1002/bmm2.70095 · Cited by 2
Deng, C., Ka, L., Ma, Y., Li, J., Li, Y. Z., Su, M., Zhou, Y., Zhang, Y., Su, J., & Zhang, Y. (2026) · Communications Biology · doi:10.1038/s42003-026-10158-3 · Cited by 2
Self-citationMao, S., Zeng, L., Yang, Y., Liu, Z., & Zhang, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1170942 · Cited by 2
Self-citationImmunosuppression and phenotypic plasticity in an atlas of human hepatocholangiocarcinoma
Li, Y., Xun, Z., Long, J., Sun, H., Yang, X., Wang, Y., Wang, Y., Xue, J., Zhang, N., Zhang, J., et al. (2024) · Hepatobiliary Surgery and Nutrition · doi:10.21037/hbsn-23-400 · Cited by 2
Self-citationKou, P., Yu, Y., Wang, H., Zhang, Y., Jin, Z., & Yu, F. (2024) · Molecules · doi:10.3390/molecules29112586 · Cited by 2
Self-citationLiu, H., Bao, H., Zhao, J., Zhu, F., & Zheng, C. (2024) · Translational Cancer Research · doi:10.21037/tcr-24-1829 · Cited by 2
Multiple programmed cell death patterns predict the prognosis and drug sensitivity in gastric cancer
Song, Q., Liu, S., Wu, D., & Cai, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1511453 · Cited by 3
Li, J., Zhang, J., Li, X., Liu, X., Zeng, B., Luo, J., Wang, H., Zhang, H., & Gao, X. (2025) · Advanced Science · doi:10.1002/advs.202413473 · Cited by 2
Zhu, B., Wan, H., Ling, Z., Jiang, H., & Pei, J. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01690-3 · Cited by 2
Single‐Cell Profiling of the Microenvironment in High‐Risk Neuroblastoma
Xu, Y., Ding, J., Shi, Z., & Bao, L. (2025) · IUBMB Life · doi:10.1002/iub.70029 · Cited by 2
Wu, Q., Yang, J., Zhang, D., Xu, H., Yu, Y., & Zheng, Y. (2025) · Medical Oncology · doi:10.1007/s12032-025-03028-1 · Cited by 2
Fu, J., Waks, A. G., Pimenta, E. M., Titchen, B. M., Bi, K., Camp, S. Y., Pappa, T., Keenan, T. E., Shannon, E. E., Vigneau, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66659-y · Cited by 4
Chen, Y.-T., Zhao, S., Kang, Y., Zhang, Y., & Chang, X. (2022) · Biochimica et biophysica acta. Molecular cell research · doi:10.1016/j.bbamcr.2022.119328 · Cited by 3
Self-citationA novel fatty-acid metabolism-based classification for triple negative breast cancer
Yang, X., Tang, W., He, Y., An, H., & Wang, J. (2023) · Aging · doi:10.18632/aging.204552 · Cited by 2
Acinic Cell Carcinoma of the Breast: A Case Report and Review of Literature
Atta, I. S. (2024) · Cureus · doi:10.7759/cureus.51427 · Cited by 2
Stephenson-Gussinye, A., Rendón-Bautista, L. A., Ruiz-Medina, B. E., Olais, E. B., Pérez‐Molina, R., Marcial-Medina, C., Chávarri-Guerra, Y., Soto‐Pérez‐de‐Celis, E., Morales-Alfaro, A., Esquivel-López, A., et al. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1420308 · Cited by 2
Poirier, N., Girault, I., Morello, A., Durand, J., & Seité, M. (2022) · Regular and Young Investigator Award Abstracts · doi:10.1136/jitc-2022-sitc2022.0826 · Cited by 2
An, M., Mehta, A., Min, B., Heo, Y. J., Parikh, M., Bi, L., Cristescu, R., Lee, H., Kim, T. J., Lee, S.-Y., et al. (2023) · medRxiv · doi:10.1101/2023.04.03.23288062 · Cited by 2
Ghisoni, E., Benedetti, F., Minasyan, A., Cunnea, P., Grimm, A. J., Fahr, N., Desbuisson, M., Capt, C., Rayroux, N., Gulhan, D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.02.590528 · Cited by 2
TimiGP-Response: the pan-cancer immune landscape associated with response to immunotherapyPreprint
Li, C., Wei, H., Reuben, A., Wang, L., Maitra, A., Zhang, J. J., & Cheng, C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.21.600089 · Cited by 2
Scholten, D., El-Shennawy, L., Jia, Y., Zhang, Y., Hyun, E., Reduzzi, C., Hoffmann, A. D., Almubarak, H. F., Tong, F., Dashzeveg, N. K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.01.646421 · Cited by 2
Self-citationLin, J., Feng, D., Liu, J., Yang, Y., Wei, X., Lin, W., & Lin, Q. (2023) · Aging · doi:10.18632/aging.204963 · Cited by 1
Ciarka, A., Kunc, M., Popęda, M., Łacko, A., Radecka, B. S., Braun, M., Pikiel, J., Litwiniuk, M. M., Pogoda, K., Iżycka‐Świeszewska, E., et al. (2024) · Współczesna Onkologia · doi:10.5114/wo.2024.139375 · Cited by 1
Zhou, L., Zhu, J.-Q., Kou, J.-T., Xu, W., Lyu, S.-C., Du, G.-S., Yang, H.-W., Wang, J.-F., Hu, X.-P., Yu, C., et al. (2024) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2024.10.001 · Cited by 1
Self-citationWang, Z., Li, J., Wang, F., Chen, C., Wu, X., Guo, W., Li, C., Luo, Y., Zhang, G., Zhang, S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-77389-4 · Cited by 1
Tan, C., Wu, D., Yang, X., Zhang, S., Liu, S., Yu, B., Yu, X., Xiu, Y., & Huang, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e41180 · Cited by 1
Self-citationIntrinsic subtype and immunity score in identification of triple-negative breast cancer at low risk
Ren, X., Zhou, T., Song, Y. M., Wu, H., Chou, J.-H., Miller, L. D., Liang, Z., & Shen, S. (2025) · The Breast · doi:10.1016/j.breast.2025.103889 · Cited by 1
Wan, H., Ling, Z., Xie, Y.-W., Jiang, H., Ruan, Z., Yang, D.-S., Yang, X.-W., & Pei, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1534981 · Cited by 1
Sun, Y., Li, Y., Han, Y., Liu, C., Song, Y., & Gao, G. (2025) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001725 · Cited by 1
Zhong, L., Feng, Z., Li, F., Zhao, H., Zhang, Z., Zhang, W., Hermeking, H., & Shi, L. (2025) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2025.110551 · Cited by 1
Self-citationJiao, J., Lv, Z., Zhang, K., Wang, R., Shi, X., Liu, L., Jiao, J., Niu, Y., & Guo, L. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.112118 · Cited by 1
Shorer, O., Amit, R., & Yizhak, K. (2025) · bioRxiv · doi:10.1016/j.xgen.2026.101328
VSIG4 Is Dispensable for Tumor Growth and Metastasis in Murine Colorectal and Breast Cancer Models
Lebegge, E., Jumapili, N. A., Craenenbroeck, J. V., Kancheva, D., Kiss, M., Barthelmess, R. M., Hamouda, A. E. I., Elkrim, Y., Raes, G., Hadadi, É., et al. (2025) · Cancers · doi:10.3390/cancers17193207 · Cited by 1
Recent advances in immunotherapy for breast cancer
Guo, Y. M., Zheng, G., Yu, F., Li, L., & Sun, Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-03493-0 · Cited by 1
Issues and missed opportunities in lymph node assessment after neoadjuvant chemotherapy
Ryan, L., Provenzano, E., Grigoriadis, A. E., & Pinder, S. E. (2025) · The Journal of Pathology · doi:10.1002/path.6479 · Cited by 1
Lin, W., Li, J., Wu, J., Huang, B., Liang, J., Zhang, Y., Zhao, L., & Yao, G. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0310 · Cited by 1
Self-citationWang, M., Song, Z., Yuan, H., Liu, C., Wang, W., Yang, N., Sun, K., Zhang, S., Qin, X., Li, J., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-4392 · Cited by 1
Zeng, L., Ruan, Z., Yan, H., Qin, H., Zeng, Z., Zou, C., Huang, Z., Jiang, W., Dai, J., Xu, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67262-x · Cited by 1
Self-citationLi, S., Zhu, J., Huang, X., Ji, F., Li, J., Yao, Z., Tang, H., Liu, L., Yan, B., & Zhanghuang, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1709225 · Cited by 2
Razavi, Z.-S., Mottaghi, A., Dmitrieva, L., Fallahianshafiei, S., Olfat, E., & Ahmadi, N. (2026) · Annals of Biomedical Engineering · doi:10.1007/s10439-025-03963-0 · Cited by 1
Chen, H., Lu, W., Zhou, Y., Guo, X., Wu, S., & Chen, Y. (2026) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s571054 · Cited by 1
Self-citationXu, X., Li, J., Zhang, X., Yq, S., Xi, L., Zhang, L., & Zhang, Y. (2026) · International Forum of Allergy & Rhinology · doi:10.1002/alr.70098 · Cited by 1
Self-citationThe interplay between cytokines and immune checkpoints in breast cancer therapy
Wu, Y., Zhu, Y. F., Cang, Q., Shaibu, Z., Kong, L., Zhou, Q., Li, X., & Yin, L. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189539 · Cited by 1
GPR183 ‐mediated activation of PI3K is a potential biomarker for immunotherapy in lung cancer
Ye, L., Zheng, N., Liu, F., Fu, H., Liu, Y., Yang, Y., Qi, R., Wu, D., Lin, S., & Song, D. (2026) · Clinical and Translational Discovery · doi:10.1002/ctd2.70119 · Cited by 1
Ni, Z., Gu, J., Qiu, Q., Li, Y., Tian, Z., Liu, G., Mei, J., Yang, J., & Sun, L. (2026) · BMC Cancer · doi:10.1186/s12885-026-15652-9 · Cited by 1
ITGB1 Regulates Triple‐Negative Breast Cancer Development by Modulating the Tumor Microenvironment
Song, N., Chen, S., Wang, L., Dang, J., Cao, X., Singh, S., Yang, L., Wang, J., Rosen, S. T., Wang, Y., et al. (2026) · Advanced Science · doi:10.1002/advs.202513672 · Cited by 2
Self-citationHuang, L., Hou, H., Zhang, X., Dong, L., Shi, W., Liu, M., Sun, J., Prakash, A., Song, H., Pei, S., et al. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70611 · Cited by 1
Mammographic radiomics and breast density for predicting PD-L1 expression in breast cancer
ZHAO, Y.-S., Li, H., Zhao, C., Wang, Y., Wang, P., Xie, Z.-Y., Ji, Y., & Lu, H. S. (2026) · Cancer Imaging · doi:10.1186/s40644-026-01001-3 · Cited by 1
Self-citationShen, Q. X., Liu, H. J., Xue, H., Yilixiati, A., Yan, S., Li, W., & Song, N. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1687326 · Cited by 1
Dong, Y.-C., Xu, X., Si, H.-J., Li, Y., Yang, D.-L., Chen, J.-Y., Wang, Y.-Z., Zhang, H.-M., Yang, L., Xie, H.-K., et al. (2026) · i Medicina · doi:10.1016/j.medj.2026.101027 · Cited by 1
Self-citationBreast cancer inequities: the intersectional role of social epidemiology and tumor biology
Peiris, M. N., Dedeoglu, A. S., Smidt, I., Suzuki, A., Rheinbay, E., Ilinski, A., Chen, J. G., Imafidon, O., Ennis, C. S., Mahdaviani, K., et al. (2026) · Cancer Causes & Control · doi:10.1007/s10552-026-02138-z · Cited by 1
Weng, J., Xu, W., Wang, F. Q., Zhao, L., Ju, F., Teng, R., Wu, D., Luo, L., Du, Y., Wang, Y., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-1138 · Cited by 1
Self-citationWang, Y., Haase, S., Whitman, A., Beltran, A., Spanheimer, P., & Brunk, E. C. (2026) · iScience · doi:10.1016/j.isci.2026.115445 · Cited by 1
Self-citationTong, Z., Gao, L., Wang, D., Zhao, P., Bao, X., Zhang, H., Dai, X., Liu, L., Zhu, X., Gao, Y., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01387-0 · Cited by 1
Liu, H., Yuan, M., Shang, Y., Chen, J., Hou, F., Wang, L., & Jiang, W. (2026) · Advanced Science · doi:10.1002/advs.202513246 · Cited by 1
Chen, D., Liu, Y., Shi, D., Li, S., Wang, Y., Wang, Q., Feng, T., Pei, S., Wang, Y., Zhang, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71819-9 · Cited by 2
Self-citationShi, X., Li, S., Bai, M., Xie, Z., 程庆保, Qiu, X., Tao, Z. Y., Jiang, X., Yang, S., Hu, J., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101860 · Cited by 1
Self-citationGao, L., & Ke, S. (2026) · Cancer Medicine · doi:10.1002/cam4.71863 · Cited by 1
Cheng, J., Lu, J., Gao, Z., Xiao, Y., Chen, P. J., Zhou, M., Huang, D. J. Y., Zhao, Z., Zhang, X., Zhao, Y., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013637 · Cited by 1
Self-citationChen, Y., Xiao, Y., Zhang, T., & Wang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1784463 · Cited by 1
Ya, Z., Wu, H., Jia, W., Li, Y., Zhu, M., Zhang, L., Zong, Y., Guo, S., Bouakaz, A., & Wan, M. (2026) · Acta Biomaterialia · doi:10.1016/j.actbio.2026.05.047 · Cited by 1
CCR5+ CD8+ T Cells Are Associated with Poor Response to PD-1 Blockade Therapy
Zhao, Z., Liu, Y., Wu, Z., Qi, C., Ning, Y., Lin, Y., Pang, X., Qiang, G., & Wang, W.-J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114963 · Cited by 1
Sun, X., Shen, L., Wang, L., Zhang, X., Lu, Z., Tang, J. P., & Li, M. (2026) · Bioinformatics · doi:10.1093/bioinformatics/btag269 · Cited by 1
Self-citationLiu, Y., Cao, W., Jin, Y., & Xu, W. (2026) · PLoS ONE · doi:10.1371/journal.pone.0354524 · Cited by 1
Wang, W., Chen, L., Guo, W., Hu, M., Han, X., Xia, X., Xu, W., & Ma, W. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1883663 · Cited by 1
Metadata
- Authors
- Zhang, Y., Chen, H., Mo, H., Hu, X., Gao, R., Zhao, Y., Liu, B., Niu, L., Sun, X., Yu, X., Wang, Y., Chang, Q., Gong, T., Guan, X., Hu, T., Qian, T., Xu, B., Ma, F., Zhang, Z., & Liu, Z.
- Affiliations
- Peking University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Cancer Hospital of Huanxing Chaoyang District Beijing (CN)
- Corresponding author
- Xu, Binghe
- Ma, Fei
- Zhang, Zemin
- Liu, Zhihua
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2021-12
- Volume
- 39
- Issue
- 12
- Pages
- 1578-1593.e8
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W3205385275
- Cited by
- 783
- References
- 77
- Citations by year
- 2026: 135 · 2025: 206 · 2024: 183 · 2023: 158 · 2022: 93 · 2021: 8
- FWCI
- 41.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (31991171, 81988101, 82030089, 91942307)
- Chinese Academy of Meteorological Sciences (2016-I2M-1-001, 2017-I2M-3-004, 2019-I2M-1-003)
- Peking University
- Beijing Municipal Science and Technology Commission (Z201100005320014)
- National Key Research and Development Program of China (2018YFC1312101, 2020YFA0803300)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- triple-negative breast cancer, PD-L1 blockade, atezolizumab, paclitaxel, immune cell dynamics, lymphoid tissue inducer cells, follicular B cells, conventional type 1 dendritic cells, single-cell RNA sequencing, single-cell ATAC-seq
- MeSH terms
- Immune Checkpoint Inhibitors, Female, Humans, Single-Cell Analysis, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
